Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Medi-Solfen® has the potential to offer a unique innovative approach to providing anaesthesia within the Accident and Emergency environment including the Ambulance Service

In the UK there are 135 emergency units1. Within England the number of attendances in 2016 was 23.7m2 (65% attending Major Emergency Departments). In 2001, the Department of Health published the paper Reforming emergency care3 and introduced a compulsory national target for England. The target required that by 2004 no-one should wait more than 4 hours in the Emergency Department. In December 2017 just 85.1% of patients at A&E were seen within 4 hours. The figures are even worse for what the NHS calls Type 1 A&E Departments – a Consultant led 24 hour service with full resuscitation facilities and designated accommodation for emergency patients – where just 77.3 per cent of patients were seen within 4 hours4. This time limit produced significant changes in the way many departments and hospitals dealt with their workload in the Emergency Department, and included many initiatives to reduce the total time and redirect patients with low acuity to alternative healthcare providers. One of the most noteworthy changes was the review of the process of “triage” and the change of the primary objective of triage—to allocate the patient to the most appropriate practitioner or area within the healthcare system, thus producing different streams or queues of patients waiting for dedicated teams of workers5.

Emergency care providers have developed a high level of expertise in acute wound management. As an example over 703,000 lacerations presented in UK Emergency Departments between 2015 In the case of this wound type considerations must be given to assessment, irrigation and closure techniques. No single approach can be applied to all wounds; however, a systematic approach to acute wound care integrated with current best practices can provide the framework for exceptional wound management. During the treatment pathway associated with laceration management it may be necessary to administer local anaesthetics to the injured site. While there are numerous commercially available topical anaesthetic agents, most of these require 10 to 30 min to become effective. The combination of lidocaine/prilocaine may have a delayed onset of 1 to 2 h ]. If a more rapid anaesthetic response is needed, injectable lidocaine (1%), bupivicaine (0.25%), or procaine (1%) are commonly used. While these drugs remain the mainstay of anaesthesia for cutaneous repair, the associated pain on injection remains a major drawback6.

Of relevance to the benefits associated with the use of Medi-Solfen®, rapid pain relief following application to traumatic wounds at initial triage and assessment would help patients better manage their extended wait periods before consultation with Lead Clinical Professionals. Once in the presence of the attending Physician, the rapid onset of additional anaesthesia (if required) without using the potential painful technique of fluid injection prior to debridement, irrigation and subsequent closure again offers measureable patient benefits. The product could also be re-applied prior to surgical closure if considered clinically necessary. The same approach could be made with minor painful wounds that present, especially in children.

An essential component of the Emergency Services is the rapid response vehicles (ambulances) that transfer patients from the site of injury to the Accident and Emergency Department. It is estimated in the UK there are close to 5,000 vehicles of this kind. This does not include Emergency Responders or the Air Ambulance Service. The inclusion of Medi-Solfen® within emergency vehicles could provide a valuable option to achieve rapid pain relief to appropriate breaks in the skin during treatment at the site of injury, transfer to hospital and provide anaesthetic cover during the reported ever increasing wait times prior to hand over to the hospital-based team.

References

  1. https://inews.co.uk/nhs/nhs-crisis-revealed-overhaul-means-dozens-of-ae-units- face-closure/
  2. Baker C. House of commons library paper 6964, 21st Feb 2017. Accident and Emergency Statistics Demand, Performance and Pressure
  3. Department of Health Reforming emergency care: first steps to a new approach. Crown Copyright. London: DOH, 2001
  4. https://inews.co.uk/news/health/accident-emergency-waiting-times-nhs-england- record-high/
  5. Lyons M, Brown R and Wears R (2007) Factors that affect the flow of patients through Triage. Emerg Med J; 24(20): 78-85.
  6. Bret A, Ayello E, Woo K et al (2010) Acute wound management; Revisiting the approach to the assessment, irrigation and closure considerations.